Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Omega Healthcare Investors (OHI)

Omega Healthcare raises 2025 AFFO guidance to $3.04-$3.07 per share after Q2 gains

Positive Impact 4 of 5 guidance Written later

Omega Healthcare Investors reported second-quarter 2025 net income of $140 million and adjusted funds from operations (AFFO) of $232 million, both up from a year earlier, and raised its full-year 2025 AFFO guidance to $3.04 to $3.07 per share from $2.95 to $3.01. The company also disclosed that tenant Genesis Healthcare filed for Chapter 11 bankruptcy on July 9, 2025, and said it expects to keep receiving full rent from Genesis during the process.

Key points

  • Q2 2025 AFFO was $232 million, or $0.77 per share, versus $185 million, or $0.71 per share, in Q2 2024.
  • Q2 2025 net income was $140 million, or $0.46 per share, versus $117 million, or $0.45 per share, a year earlier.
  • Full-year 2025 AFFO guidance was raised to $3.04 to $3.07 per diluted share from $2.95 to $3.01.
  • Genesis filed for Chapter 11 on July 9, 2025; Omega agreed to provide an $8.0 million debtor-in-possession financing.

The filing

CompanyOmega Healthcare Investors (OHI)
Form8-K, current report
Filed with the SECJul 31, 2025, 4:17 PM ET
Accession number0000888491-25-000022

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.